Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leptospira interrogans serovar Canicola antigens are a group of immunogenic proteins and surface components derived from the Canicola serovar of the pathogenic spirochete Leptospira interrogans (nih.gov, 1.1.1). These antigens include major outer membrane proteins (OMPs) such as LipL32, LipL41, and OmpL1, as well as Leptospiral immunoglobulin-like (Lig) proteins, which are critical for the bacterium's pathogenesis and host interaction (nih.gov, 1.3.3; frontiersin.org, 1.1.2). LipL32, the most abundant lipoprotein, is highly conserved among pathogenic Leptospira species and facilitates adhesion to host extracellular matrix components like laminin and collagen (scirp.org, 1.3.1). These antigens are the primary components of veterinary vaccines, such as Nobivac L4 and Vanguard L4, which are designed to induce protective humoral and cellular immunity against leptospirosis (msd-animal-health.co.in, 1.2.4; mdpi.com, 1.2.5). Leptospirosis is a significant zoonotic disease that can lead to severe renal and hepatic failure in both animals and humans (nih.gov, 1.4.2). In addition to their role in immunization, these antigens serve as critical targets in diagnostic assays, such as the Microscopic Agglutination Test (MAT) and ELISA, to detect host-produced antibodies (nih.gov, 1.3.3). The interaction between these antigens and the host immune system is the basis for both protective immunity and the serological diagnosis of the infection (researchgate.net, 1.3.2).
Induction of active immunity through the presentation of bacterial epitopes to the host immune system, leading to the production of neutralizing antibodies and the activation of T-cell responses.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leptospira interrogans serovar Canicola antigens.